SVRA Savara Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1160308 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-32.1%
TTM EPS YoY-13.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-151.0%
ROA-102.9%
ROIC (approx.)-114.7%
Asset turnover—
Leverage & solvency
Liabilities / assets30.8%
Debt / equity0.28x
Current ratio8.55x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-15.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $81.40M | $78.03M |
| SG&A expense | $42.06M | $25.04M |
| Operating income | -$123.55M | -$103.20M |
| Pretax income | -$118.84M | -$95.88M |
| Income tax | $0 | $9,000 |
| Net income | -$118.84M | -$95.88M |
| EBITDA | -$123.46M | -$103.07M |
| EPS (basic) | -0.53 | -0.48 |
| EPS (diluted) | -0.53 | -0.48 |
| Weighted avg. shares (diluted) | 222.39M | 198.19M |
| Balance sheet | ||
| Cash & equivalents | $33.18M | $15.13M |
| Short-term investments | $202.52M | $181.20M |
| Current assets | $241.62M | $202.13M |
| PP&E, net | $100,000 | $165,000 |
| Total assets | $253.44M | $212.88M |
| Current liabilities | $20.40M | $14.72M |
| Short-term debt | $0 | $0 |
| Long-term debt | $29.91M | $26.62M |
| Total debt | $29.91M | $26.62M |
| Total liabilities | $50.30M | $41.43M |
| Shareholders' equity | $203.13M | $171.45M |
| Net debt | -$3.27M | $11.49M |
| Shares outstanding | 204.57M | 172.42M |
| Cash flow statement | ||
| Operating cash flow | -$101.04M | -$89.09M |
| Capital expenditure | $22,000 | $25,000 |
| Free cash flow | -$101.06M | -$89.11M |
| Investing cash flow | -$18.44M | -$39.94M |
| Financing cash flow | $137.81M | $117.58M |
| Depreciation & amortization | $87,000 | $130,000 |
| Stock-based compensation | $14.42M | $9.86M |
Free plan shows the latest 2 periods; Pro shows all 29 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.